Prelude Therapeutics Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This annual filing was signed March 16, 2021; it is not a quarterly report. Prelude is a clinical-stage precision oncology company with no approved products or product revenue.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $48.2 million | $24.3 million |
| General and administrative expense | $10.6 million | $3.8 million |
| Total operating expenses / operating loss | $58.8 million | $28.1 million |
| Other income, net | $1.8 million | $0.5 million |
| Net loss | $56.9 million | $27.6 million |
| Cash used in operating activities | $46.2 million | $25.7 million |
| Cash and cash equivalents at year-end | $218.3 million | $18.9 million |
Margins are not meaningful because the company had no revenue. R&D costs rose primarily with clinical trial activity, including PRT543, PRT811 and the launch of PRT1419; G&A rose with staffing, professional fees and public-company costs. Other income included Delaware R&D tax-credit income and interest. Accumulated deficit was $107.4 million.
FY2020 financing provided $246.2 million, including $166.6 million net IPO proceeds and $79.8 million net proceeds from Series B and Series C preferred stock. In January 2021, Prelude raised a further $161.4 million net from a common-stock offering. Management expects year-end cash plus the January proceeds to fund operating expenses and capital expenditures into 2023; this estimate depends on assumptions and could prove inaccurate. Current liabilities were $11.4 million at year-end; the balance sheet reported no capital-lease obligation then. No material funded debt is identified in the provided financial statements.
Business, pipeline and notable changes
The company reported six programs across clinical and preclinical development. Its three clinical-stage candidates were in Phase 1: PRT543 and brain-penetrant PRT811, both PRMT5 inhibitors, and oral PRT1419, an MCL1 inhibitor. PRT2527, a CDK9 inhibitor, and programs involving SMARCA2 degradation and a kinase target were earlier-stage efforts.
- PRT543: The Phase 1 dose-escalation portion was completed; the ACC expansion cohort was open. By December 16, 2020, 61 patients had enrolled. The company reported an ongoing confirmed complete response in one patient with HRD-positive ovarian cancer and encouraging findings in some myelofibrosis patients. These are early, limited-patient observations, not evidence of established efficacy.
- PRT811: By December 16, 2020, 24 patients had enrolled. A patient with refractory glioblastoma had a reported 77% tumor reduction at week 18, classified as a partial response under RANO criteria. Expansion enrollment was expected by mid-2021.
- PRT1419: Four patients had enrolled in the oral Phase 1 study by December 16, 2020; the company reported no serious adverse events at that point. The FDA had cleared an IND for an IV formulation, with a solid-tumor Phase 1 study expected in the first half of 2021.
Compared with 2019, annual net loss more than doubled as operating expenses increased by $30.7 million. The company completed its IPO in September 2020, converted preferred stock into common and non-voting common stock, and materially increased cash resources. It reported no dividend payments or plans for near-term dividends.
Outlook, risks and other items
Management planned to expand PRT543 and PRT811 trials, add PRT1419 expansion and combination cohorts, begin the IV PRT1419 study, and pursue additional IND-enabling work. It aims to produce a new IND every 12–18 months. These are forward-looking plans, not assured outcomes; no product-sales guidance was provided.
- All lead candidates remain early in development; trials may fail, reveal safety issues, enroll slowly or require additional time and funding. Reported clinical responses are preliminary and may change with further data.
- COVID-19 had caused limited site-initiation, participation and enrollment delays; further effects on trials, vendors and timelines were uncertain.
- The company relies on third parties for clinical and commercial manufacturing, had no long-term supply arrangements for many supplies, and reported no redundant supply arrangements for active ingredients or drug product.
- It expects continuing losses and may need additional capital after its projected runway; financing could dilute shareholders or require concessions on pipeline rights.
- Competition, regulatory approval, intellectual-property protection, reimbursement, and the ability to build commercial capabilities are material uncertainties. The filing reported no material pending legal proceeding.
- The independent auditor issued an unqualified opinion on the financial statements. The filing states that neither management nor the auditor performed an internal-control-over-financial-reporting evaluation for this annual report; management said disclosure controls were effective at a reasonable-assurance level.
Important facts for investors to verify
- Check subsequent filings for updated cash, spending, financing and whether the projected runway into 2023 remains supportable.
- Review full, updated trial disclosures for patient counts, response durability, safety, dose selection and expansion progress; distinguish preliminary Phase 1 observations from confirmed efficacy.
- Assess potential dilution from equity compensation, future financing and the non-voting common stock’s conversion provisions. The filing reported 46,585,860 common shares outstanding on March 12, 2021.
- Verify the cover-page shell-company checkbox: the supplied filing text marks “Yes,” despite describing an operating clinical-stage biotechnology business.
- Review the 2021 proxy statement for ownership, governance and compensation information incorporated by reference into Part III.